Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment

MLA

Doris Damian, et al. “Efficacy of Cladribine Tablets in High Disease Activity Patients with Relapsing Multiple Sclerosis: Post Hoc Analysis of Subgroups with and without Prior Disease-Modifying Drug Treatment.” Current Medical Research and Opinion, vol. 37, Feb. 2021, pp. 459–64. EBSCOhost, https://doi.org/10.1080/03007995.2020.1865888.

APA

Doris Damian, Schiffon L. Wong, Gerard Harty, Fernando Dangond, Dominic Jack, Patrick Vermersch, & Andrew Galazka. (2021). Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Current Medical Research and Opinion, 37, 459–464. https://doi.org/10.1080/03007995.2020.1865888

Chicago

Doris Damian, Schiffon L. Wong, Gerard Harty, Fernando Dangond, Dominic Jack, Patrick Vermersch, and Andrew Galazka. 2021. “Efficacy of Cladribine Tablets in High Disease Activity Patients with Relapsing Multiple Sclerosis: Post Hoc Analysis of Subgroups with and without Prior Disease-Modifying Drug Treatment.” Current Medical Research and Opinion 37 (February): 459–64. doi:10.1080/03007995.2020.1865888.